Among the glioma IDH-mutant group, 1p/19q codeleted oligodendroglioma had a better prognosis (median survival not reached) than did patients with an astrocytoma subclass (median survival 115 months), who in turn had better prognosis than patients with high-grade astrocytoma subclass (median survival 60 months). The gene discussed is IDH2; the disease is glioma.